Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 3 2Phase 1/2 2Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 7Genitourinary 2Gastrointestinal 2Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Prostatic Neoplasms 1Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 69Docetaxel 50Nivolumab 44Prednisone 34enzalutamide 30Gemcitabine 26Cyclophosphamide 22Cisplatin 22Paclitaxel 21Radiotherapy 19Carboplatin 19Bevacizumab 19Abiraterone Acetate 18Ipilimumab 17atezolizumab 14Magnetic Resonance Spectroscopy 14fludarabine 13aldesleukin 13Sunitinib 13Interleukin-2 12avelumab 11Radiosurgery 11Pluvicto 11Filgrastim 11Everolimus 11gallium 68 PSMA-11 10fludarabine phosphate 10enfortumab vedotin 10durvalumab 10cemiplimab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Thalidomide × Genitourinary × Clear all
NCT00038246 2018-10-31

Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma

M.D. Anderson Cancer Center

Phase 1/2 Completed
40 enrolled
Genitourinary

Prostatic Neoplasms

NCT00277017 2011-09-27

Combination Therapy With 5-Fluorouracil, Interferon-an Interleukin-2, & Thalidomide for Metastatic, Advanced or Recurrent Renal Cell Carcinoma

New Mexico Cancer Research Alliance

Phase 1/2 Completed
15 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡